Skip to the page

Data / Form D filings / Project Samri Inc.

Project Samri Inc.: Form D filing

Project Samri Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2023. The latest, on November 13, 2023, reports $10.5 million sold of a $10.5 million offering to 18 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
6 LIBERTY SQUARE, #405, Boston, MA, 02109
Phone
(917) 554-0580
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2023
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1999089

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Nov 13, 2023New notice$10,500,001$10,500,00118Oct 27, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Kent WakefordExecutive Officer, Director, Promoter
James KimDirector
Benjamin LammDirector
Vaskar GnyawaliExecutive Officer
Sukanya Srinivasa Rao Arun PunthambakerExecutive Officer

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Nov 13, 2023 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Project Samri Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.